vs
Orthofix Medical Inc.（OFIX）与RAYONIER INC（RYN）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是RAYONIER INC的1.9倍（$219.9M vs $117.5M），RAYONIER INC净利率更高（22.1% vs -1.0%，领先23.1%），Orthofix Medical Inc.同比增速更快（2.0% vs -81.9%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Rayonier Inc.是总部位于佛罗里达州怀尔德莱特的林地房地产投资信托（REIT），资产分布在美国和新西兰的软木种植区域，核心业务板块为木材业务与房地产业务。
OFIX vs RYN — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$117.5M
营收增速更快
OFIX
高出83.9%
-81.9%
净利率更高
RYN
高出23.1%
-1.0%
两年增速更快
OFIX
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $117.5M |
| 净利润 | $-2.2M | $25.9M |
| 毛利率 | 71.1% | 41.9% |
| 营业利润率 | 0.2% | 23.0% |
| 净利率 | -1.0% | 22.1% |
| 营收同比 | 2.0% | -81.9% |
| 净利润同比 | 92.4% | -92.1% |
| 每股收益（稀释后） | $-0.05 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRYN
| Q4 25 | $219.9M | $117.5M | ||
| Q3 25 | $205.6M | $177.5M | ||
| Q2 25 | $203.1M | $106.5M | ||
| Q1 25 | $193.6M | $82.9M | ||
| Q4 24 | $215.7M | $650.5M | ||
| Q3 24 | $196.6M | $124.1M | ||
| Q2 24 | $198.6M | $99.6M | ||
| Q1 24 | $188.6M | $113.7M |
净利润OFIXRYN
| Q4 25 | $-2.2M | $25.9M | ||
| Q3 25 | $-22.8M | $43.2M | ||
| Q2 25 | $-14.1M | $408.7M | ||
| Q1 25 | $-53.1M | $-3.4M | ||
| Q4 24 | $-29.1M | $327.1M | ||
| Q3 24 | $-27.4M | $28.8M | ||
| Q2 24 | $-33.4M | $1.9M | ||
| Q1 24 | $-36.0M | $1.4M |
毛利率OFIXRYN
| Q4 25 | 71.1% | 41.9% | ||
| Q3 25 | 72.2% | 32.9% | ||
| Q2 25 | 68.7% | 29.7% | ||
| Q1 25 | 62.8% | 21.7% | ||
| Q4 24 | 69.0% | 53.8% | ||
| Q3 24 | 68.7% | 30.4% | ||
| Q2 24 | 67.8% | 25.4% | ||
| Q1 24 | 67.5% | 24.3% |
营业利润率OFIXRYN
| Q4 25 | 0.2% | 23.0% | ||
| Q3 25 | -8.3% | 23.5% | ||
| Q2 25 | -7.9% | 13.7% | ||
| Q1 25 | -25.2% | 0.1% | ||
| Q4 24 | -5.3% | 47.7% | ||
| Q3 24 | -9.6% | 15.2% | ||
| Q2 24 | -12.5% | 4.6% | ||
| Q1 24 | -15.6% | 7.6% |
净利率OFIXRYN
| Q4 25 | -1.0% | 22.1% | ||
| Q3 25 | -11.1% | 24.3% | ||
| Q2 25 | -6.9% | 383.6% | ||
| Q1 25 | -27.4% | -4.1% | ||
| Q4 24 | -13.5% | 45.1% | ||
| Q3 24 | -13.9% | 23.2% | ||
| Q2 24 | -16.8% | 1.9% | ||
| Q1 24 | -19.1% | 1.2% |
每股收益（稀释后）OFIXRYN
| Q4 25 | $-0.05 | $0.14 | ||
| Q3 25 | $-0.57 | $0.28 | ||
| Q2 25 | $-0.36 | $2.63 | ||
| Q1 25 | $-1.35 | $-0.02 | ||
| Q4 24 | $-0.76 | $2.18 | ||
| Q3 24 | $-0.71 | $0.19 | ||
| Q2 24 | $-0.88 | $0.01 | ||
| Q1 24 | $-0.95 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $842.9M |
| 总债务越低越好 | — | $845.3M |
| 股东权益账面价值 | $450.0M | $2.2B |
| 总资产 | $850.6M | $3.4B |
| 负债/权益比越低杠杆越低 | — | 0.38× |
8季度趋势，按日历期对齐
现金及短期投资OFIXRYN
| Q4 25 | $82.0M | $842.9M | ||
| Q3 25 | $62.9M | $919.6M | ||
| Q2 25 | $65.6M | $892.3M | ||
| Q1 25 | $58.0M | $216.2M | ||
| Q4 24 | $83.2M | $303.1M | ||
| Q3 24 | $30.1M | $51.9M | ||
| Q2 24 | $26.4M | $120.2M | ||
| Q1 24 | $27.0M | $142.1M |
总债务OFIXRYN
| Q4 25 | — | $845.3M | ||
| Q3 25 | $157.2M | $845.1M | ||
| Q2 25 | $157.0M | $844.9M | ||
| Q1 25 | $156.9M | $1.0B | ||
| Q4 24 | $157.0M | $1.0B | ||
| Q3 24 | $118.5M | $1.3B | ||
| Q2 24 | $118.0M | $1.4B | ||
| Q1 24 | $118.2M | $1.4B |
股东权益OFIXRYN
| Q4 25 | $450.0M | $2.2B | ||
| Q3 25 | $442.5M | $2.3B | ||
| Q2 25 | $458.3M | $2.3B | ||
| Q1 25 | $458.3M | $1.9B | ||
| Q4 24 | $503.1M | $1.8B | ||
| Q3 24 | $525.9M | $1.8B | ||
| Q2 24 | $546.0M | $1.8B | ||
| Q1 24 | $570.3M | $1.8B |
总资产OFIXRYN
| Q4 25 | $850.6M | $3.4B | ||
| Q3 25 | $832.6M | $3.5B | ||
| Q2 25 | $837.2M | $3.5B | ||
| Q1 25 | $823.1M | $3.4B | ||
| Q4 24 | $893.3M | $3.5B | ||
| Q3 24 | $867.9M | $3.5B | ||
| Q2 24 | $882.0M | $3.5B | ||
| Q1 24 | $906.0M | $3.6B |
负债/权益比OFIXRYN
| Q4 25 | — | 0.38× | ||
| Q3 25 | 0.36× | 0.37× | ||
| Q2 25 | 0.34× | 0.37× | ||
| Q1 25 | 0.34× | 0.55× | ||
| Q4 24 | 0.31× | 0.59× | ||
| Q3 24 | 0.23× | 0.72× | ||
| Q2 24 | 0.22× | 0.75× | ||
| Q1 24 | 0.21× | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $256.7M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 9.91× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXRYN
| Q4 25 | $27.7M | $256.7M | ||
| Q3 25 | $12.4M | $116.2M | ||
| Q2 25 | $11.6M | $61.0M | ||
| Q1 25 | $-18.4M | $27.7M | ||
| Q4 24 | $23.7M | $261.6M | ||
| Q3 24 | $11.7M | $66.2M | ||
| Q2 24 | $9.0M | $55.3M | ||
| Q1 24 | $-18.6M | $52.3M |
自由现金流OFIXRYN
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | $99.9M | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | $42.2M | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXRYN
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | 56.3% | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | 34.0% | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXRYN
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | 9.2% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | 19.3% | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXRYN
| Q4 25 | — | 9.91× | ||
| Q3 25 | — | 2.69× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.80× | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 29.07× | ||
| Q1 24 | — | 38.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RYN
| Real Estate Segment | $42.3M | 36% |
| Pacific Northwest Timber Segment | $19.8M | 17% |
| Stumpage Pay As Cut | $19.3M | 16% |
| Improved Development | $14.8M | 13% |
| Nontimber | $13.2M | 11% |
| License Revenue Primarily From Hunting | $5.3M | 4% |
| Land Based Solutions | $2.9M | 2% |
